BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Roche (RHHBY)'s Avastin Disappoints Against Ovarian Cancer


12/29/2011 10:02:44 AM

Two studies found that Genentech's cancer drug Avastin failed to prolong life on patients, but kept their disease from worsening for a time, the Washington Post reports.

The two studies released Thursday showed the drug could slow the growth of ovarian cancer when added to chemotherapy, news that was welcomed by patient advocates, who point to the lack of new treatments for the disease.

With the mixed results, though, Genentech said it was unlikely at this time to seek Food and Drug Administration approval of Avastin for ovarian cancer.



Read at USA Today
Read at CBS News
Read at Time
Read at Washington Post
Read at San Francisco Business Times

Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES